Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

Inclusion Criteria: 1. Histologically confirmed esophageal squamous cell carcinoma 2. Clinical stage T2N0 (invasion to muscularis propria) or T3N0 (invasion to adventitia) 3. ECOG performance 0 or 1 4. Age 19 years or older Exclusion Criteria: 1. Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal cancer 2. Ineligibility or contraindication for esophagectomy 3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. 4. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). 5. Has severe hypersensitivity and adverse events (≥Grade 3) to nivolumab and/or any PD-1/PD-L1 inhibitors.